Cargando…
P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431250/ http://dx.doi.org/10.1097/01.HS9.0000846524.06649.c4 |
| _version_ | 1784780001736916992 |
|---|---|
| author | Kastritis, E. Palladini, G. Dimopoulos, M. A. Jaccard, A. Merlini, G. Theodorakakou, F. Fotiou, D. Minnema, M. C. Wechalekar, A. Gkolfinopoulos, S. Manousou, K. Sonneveld, P. Schönland, S. |
| author_facet | Kastritis, E. Palladini, G. Dimopoulos, M. A. Jaccard, A. Merlini, G. Theodorakakou, F. Fotiou, D. Minnema, M. C. Wechalekar, A. Gkolfinopoulos, S. Manousou, K. Sonneveld, P. Schönland, S. |
| author_sort | Kastritis, E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431250 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94312502022-08-31 P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK Kastritis, E. Palladini, G. Dimopoulos, M. A. Jaccard, A. Merlini, G. Theodorakakou, F. Fotiou, D. Minnema, M. C. Wechalekar, A. Gkolfinopoulos, S. Manousou, K. Sonneveld, P. Schönland, S. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431250/ http://dx.doi.org/10.1097/01.HS9.0000846524.06649.c4 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Kastritis, E. Palladini, G. Dimopoulos, M. A. Jaccard, A. Merlini, G. Theodorakakou, F. Fotiou, D. Minnema, M. C. Wechalekar, A. Gkolfinopoulos, S. Manousou, K. Sonneveld, P. Schönland, S. P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title | P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_full | P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_fullStr | P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_full_unstemmed | P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_short | P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_sort | p914: efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: a phase 2 study by the european myeloma network |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431250/ http://dx.doi.org/10.1097/01.HS9.0000846524.06649.c4 |
| work_keys_str_mv | AT kastritise p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT palladinig p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT dimopoulosma p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT jaccarda p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT merlinig p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT theodorakakouf p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT fotioud p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT minnemamc p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT wechalekara p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT gkolfinopouloss p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT manousouk p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT sonneveldp p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT schonlands p914efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork |